Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.74 |
| ▸ | RAF1 | P04049 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.56 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 5/20 | 0.53 |
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.53 |
| ▸ | CA9 | Q16790 | 5/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4354878 | 0.87 | MEN1 (0.73) | MEN1MAPTKMT2ALMNANPSR1 | |
| SCHEMBL20211616 | 0.86 | MEN1 (1.00) | MEN1MAPTKMT2ALMNANPSR1 | |
| SCHEMBL30516130 | 0.86 | MEN1 (1.00) | MEN1MAPTKMT2ALMNANPSR1 | |
| SCHEMBL4355989 | 0.84 | STK39 (0.67) | MEN1MAPTKMT2ALMNANPSR1 | |
| SCHEMBL4347461 | 0.84 | NPC1 (0.59) | MEN1MAPTKMT2ALMNANPSR1 | |
| SCHEMBL4354102 | 0.83 | TRPV1 (0.58) | MEN1MAPTKMT2ALMNANPSR1 | |
| SCHEMBL4350770 | 0.82 | MEN1 (0.67) | MEN1MAPTKMT2ALMNANPSR1 | |
| SCHEMBL4350274 | 0.82 | EPHX2 (0.64) | MEN1MAPTKMT2ALMNANPSR1 | |
| SCHEMBL30053559 | 0.81 | CA12 (0.73) | MEN1MAPTKMT2ALMNANPSR1 | |
| SCHEMBL3706592 | 0.80 | KMT2A (0.75) | MEN1MAPTKMT2ALMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| CN-1701061-A | Novel compounds for inhibiting rotamase enzymes and uses thereof | JERINI AG (DE) | 2005-11-23 | — | — | CN | claimed |
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | MEN1 2168/4885MAPT 4439/4885KMT2A 2096/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | MEN1 3901/4885MAPT 4184/4885KMT2A 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.